Natera Inc (NASDAQ:NTRA) was the target of a significant decline in short interest in the month of August. As of August 15th, there was short interest totalling 1,074,198 shares, a decline of 28.8% from the July 31st total of 1,509,612 shares. Currently, 2.8% of the shares of the stock are sold short. Based on an average trading volume of 597,830 shares, the days-to-cover ratio is currently 1.8 days.

Shares of Natera stock opened at $28.23 on Wednesday. The company has a current ratio of 1.69, a quick ratio of 1.56 and a debt-to-equity ratio of -3.32. The stock has a market cap of $1.76 billion, a price-to-earnings ratio of -11.76 and a beta of 2.12. Natera has a 1-year low of $8.60 and a 1-year high of $29.62.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, August 8th. The medical research company reported ($0.55) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.55). The firm had revenue of $63.07 million for the quarter, compared to analysts’ expectations of $61.71 million. Natera had a negative net margin of 59.07% and a negative return on equity of 752.93%. The company’s quarterly revenue was up 20.6% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.55) earnings per share. equities analysts anticipate that Natera will post -2.05 EPS for the current year.

In related news, CFO Michael Burkes Brophy sold 26,870 shares of the company’s stock in a transaction dated Monday, July 2nd. The shares were sold at an average price of $18.29, for a total value of $491,452.30. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, COO Steven Leonard Chapman sold 86,919 shares of the company’s stock in a transaction dated Monday, June 25th. The shares were sold at an average price of $18.00, for a total transaction of $1,564,542.00. Following the completion of the sale, the chief operating officer now directly owns 3,588 shares in the company, valued at approximately $64,584. The disclosure for this sale can be found here. In the last three months, insiders sold 115,797 shares of company stock worth $2,080,794. 13.18% of the stock is currently owned by insiders.

Institutional investors have recently modified their holdings of the business. State Board of Administration of Florida Retirement System bought a new stake in Natera during the second quarter worth about $200,000. Paradigm Capital Management Inc. NY bought a new stake in Natera during the second quarter worth about $207,000. Trexquant Investment LP bought a new stake in Natera during the first quarter worth about $119,000. Cubist Systematic Strategies LLC bought a new stake in Natera during the second quarter worth about $252,000. Finally, Woodmont Investment Counsel LLC bought a new stake in Natera during the second quarter worth about $258,000. 66.31% of the stock is currently owned by hedge funds and other institutional investors.

A number of analysts recently weighed in on NTRA shares. ValuEngine raised shares of Natera from a “hold” rating to a “buy” rating in a research note on Wednesday, June 6th. BidaskClub raised shares of Natera from a “hold” rating to a “buy” rating in a research note on Saturday, June 16th. Canaccord Genuity upped their target price on shares of Natera from $19.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, June 25th. Zacks Investment Research raised shares of Natera from a “hold” rating to a “buy” rating and set a $24.00 target price on the stock in a research note on Tuesday, July 17th. Finally, Craig Hallum upped their target price on shares of Natera from $23.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, August 9th. One analyst has rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $23.14.

Natera Company Profile

Natera, Inc, a diagnostics company, provides preconception and prenatal genetic testing services. It primarily offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus typically with a blood draw from the mother; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases that could be passed on to the carrier's children; and Spectrum pre-implantation genetic screening and Spectrum pre-implantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle.

Recommended Story: Understanding Stock Ratings

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.